Entrada Therapeutics, Inc.

Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on creating a new class of medicines to target previously inaccessible intracellular targets. The company is developing a portfolio of genetic medicines for conditions such as neuromuscular and inherited retinal diseases using proprietary, versatile, and modular approaches. Entrada is advancing multiple clinical programs for Duchenne muscular dystrophy (DMD) in the United Kingdom, European Union, and United States. In 2026, the company expects to have four clinical-stage programs in its DMD franchise: ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51. These exon skipping programs are estimated to be applicable to over 11,500 patients in the U.S. and Europe. The company's ELEVATE-44-201 clinical study for ENTR-601-44, targeting ambulatory DMD patients amenable to exon 44 skipping, has completed dosing for Cohort 1 of its global Phase 1/2 multiple ascending dose portion. All 8 patients in this cohort have transitioned to the 6-dose open-label portion of the trial, with dosing every 6 weeks ongoing in this Phase 2 segment. Additionally, Entrada has a partnership with Vertex Pharmaceuticals Incorporated for myotonic dystrophy type 1 (DM1), known as VX-670. All of Entrada's programs utilize the same endosomal escape vehicle.